Current management of cholangiocarcinoma

Mount Sinai Journal of Medicine

Volumn 79, Issue 2, 2012, Pages 232-245

  Singh, Manoj K ^a   Facciuto, Marcelo E ^a  

^a MOUNT SINAI MEDICAL CENTER   (United States)

Author keywords

Cholangiocarcinoma; Hepatocellular carcinoma; Liver transplantation

Indexed keywords

GEMCITABINE; PHOTOSENSITIZING AGENT;

BILE DUCT CARCINOMA; BILIARY TRACT SURGERY; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER INVASION; CANCER PALLIATIVE THERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CHOLANGIOGRAPHY; CLINICAL FEATURE; DECOMPRESSION; HUMAN; LABORATORY TEST; LIVER ATROPHY; LIVER RESECTION; LIVER TRANSPLANTATION; METASTASIS; PATIENT CARE; PHOTODYNAMIC THERAPY; PORTAL VEIN; REVIEW; STENT; ULTRASOUND;

BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; CHOLANGIOCARCINOMA; HEPATECTOMY; HUMANS; LIVER TRANSPLANTATION; NEOPLASM STAGING; PALLIATIVE CARE; TREATMENT OUTCOME;

EID: 84859806348     PISSN: 00272507     EISSN: 19317581     Source Type: Journal    
DOI: 10.1002/msj.21298     Document Type: Review

References (185)

1. Renshaw K. Malignant neoplasms of the extra-hepatic biliary ducts. Ann Surg 1922; 76: 205-221.
2. Burke EC, Jarnagin WR, Hochwald SN, et al. Hilar cholangiocarcinoma: pattern of spread, the importance of hepatic resection for curative operation and a presurgical clinical staging system. Ann Surg 1998; 228: 385-394. (Pubitemid 30191701)
3. Nakeeb A, Pitt HA, Sohn TA, et al. Cholangiocarcinoma: a spectrum of intrahepatic, perihilar and distal tumors. Ann Surg 1996; 224: 463-473.
4. Shaib Y, El-Serag HB. The epidemiology of cholangiocarcinoma. Semin Liver Dis 2004; 24: 115-125. (Pubitemid 38738341)
5. Patel T. Cholangiocarcinoma. Nat Clin Pract Gastroenterol Hepatol 2006; 3: 33-42.
6. Bismuth H, Corlette MB. Intrahepatic cholangioenteric anastomosis in carcinoma of the hilus of the liver. Surg Gynecol Obstet 1975; 140: 170-178.
7. Nakanuma Y, Curado MP, Franceschi S, et al. Intrahepatic cholangiocarcinoma. In: Bosman FT, Carneiro F, Hrubman RH, et al (eds). WHO Classification of Tumors of the Digestive System. Lyon: IARC Press; 2010: 217-224.
8. Nakanuma Y, Harada K, Ishikawa A, et al. Anatomic and molecular pathology of intrahepaticcholangiocarcinoma. J Hepatobiliary Pancreat Surg 2003; 10: 265-281.
9. Colombari R, Tsui WM. Biliary tumors of the liver. Semin Liver Dis 1995; 15: 402-413.
10. Goodman ZD. Neoplasms of the liver. Mod Pathol 2007; 20(suppl 1): S49-S60. (Pubitemid 46733654)
11. Liver Cancer Study Group of Japan. The General Rules for the Clinical and Pathological Study of Primary Liver Cancer. 5th ed. Tokyo: Kanehara; 2008.
12. Liver Cancer Study Group of Japan. National Surveillance of Primary Liver Cancer in Japan, 18th Report. Kyoto: Media Planning; 2009.
13. Guglielmi A, Ruzzenente A, Campagnaro T, et al. Intrahepatic cholangiocarcinoma: prognostic factors after surgical resection. World J Surg 2009; 33: 1247-1254.
14. Nakanuma Y, Sasaki M, Ikeda H, et al. Pathology of peripheral intrahepatic cholangiocarcinoma with reference to tumorigenesis. Hepatol Res 2008; 38: 325-334. (Pubitemid 351321174)
15. Edge SB, Byrd DR, Compton CC, et al (eds). AJCC Cancer Staging Handbook. 7th ed. New York, NY: Springer; 2010.
16. Lazaridis KN, Gores GJ. Cholangiocarcinoma. Gastroenterology 2005; 128: 1655-1667. (Pubitemid 40692558)
17. Vauthey JN, Blumgart LH. Recent advances in the management of cholangiocarcinomas. Semin Liver Dis 1994; 14: 109-114. (Pubitemid 24153079)
18. Shaib YH, Davila JA, McGlynn K, et al. Rising incidence of intrahepatic cholangiocarcinoma in the United States: a true increase? J Hepatol 2004; 40: 472-477. (Pubitemid 38230849)
19. Shaib YH, El-Serag HB, Davila JA, et al. Risk factors of intrahepatic cholangiocarcinoma in the United States: a case-control study. Gastroenterology 2005; 128: 620-626. (Pubitemid 40585364)
20. Klatskin G. Adenocarcinoma of the hepatic duct at its bifurcation within the porta hepatis: an unusual tumor with distinctive clinical and pathological features. Am J Med 1965; 38: 241-256.
21. Rosen CB, Heimbach JK, Gores GJ. Surgery for cholangiocarcinoma: the role of liver transplantation. HPB (Oxford) 2008; 10: 186-189. (Pubitemid 352016246)
22. Chapman RW. Risk factors for biliary tract carcinogenesis. Ann Oncol 1999; 10: 308-311.
23. Welzel TM, Graubard BI, El-Serag HB, et al. Risk factors for intrahepatic and extrahepatic cholangiocarcinoma in the United States: a population-based case-control study. Clin Gastroenterol Hepatol 2007; 5: 1221-1228. (Pubitemid 47496233)
24. Haswell-Elkins MR, Mairiang E, Mairiang P, et al. Cross-sectional study of Opisthorchis viverrini infection and cholangiocarcinoma in communities within a high-risk area in northeast Thailand. Int J Cancer 1994; 59: 505-509.
25. Jang KT, Hong SM, Lee KT, et al. Intraductal papillary neoplasm of the bile duct associated with Clonorchis sinensis infection. Virchows Arch 2008; 453: 589-598.
26. Su CH, Shyr YM, Lui WY, et al. Hepatolithiasis associated with cholangiocarcinoma. Br J Surg 1997; 84: 969-973. (Pubitemid 27310865)
27. Kubo S, Kinoshita H, Hirohashi K, et al. Hepatolithiasis associated with cholangiocarcinoma. World J Surg 1995; 19: 637-641.
28. Lesurtel M, Regimbeau JM, Farges O, et al. Intrahepatic cholangiocarcinoma and hepatolithiasis: an unusual association in Western countries. Eur J Gastroenterol Hepatol 2002; 14: 1025-1027.
29. Chu KM, Lo CM, Liu CL, et al. Malignancy associated with hepatolithiasis. Hepatogastroenterology 1997; 44: 352-357.
30. DeOliveira ML, Cunningham SC, Cameron JL, et al. Cholangiocarcinoma: thirty-one-year experience with 564 patients at a single institution. Ann Surg 2007; 245: 755-762. (Pubitemid 46684105)
31. Chen MF, Jan YY, Jeng LB, et al. Intrahepatic cholangiocarcinoma in Taiwan. J Hepatobiliary Pancreat Surg 1999; 6: 136-141.
32. Khan SA, Davidson BR, Goldin R, et al. Guidelines for the diagnosis and treatment of cholangiocarcinoma: consensus document. Gut 2002; 51(suppl 6):VI1-VI9. (Pubitemid 35216840)
33. Jarnagin WR. Cholangiocarcinoma of the extrahepatic bile ducts. Semin Surg Oncol 2000; 19: 156-176.
34. Pitt HA, Dooley WC, Yeo CJ, et al. Malignancies of the biliary tree. Curr Probl Surg 1995; 32: 1-90.
35. Patel AH, Harnois DM, Klee GG, et al. The utility of CA 19-9 in the diagnoses of cholangiocarcinoma in patients without primary sclerosing cholangitis. Am J Gastroenterol 2000; 95: 204-207. (Pubitemid 30041560)
36. Chen CY, Shiesh SC, Tsao HC, et al. The assessment of biliary CA 125, CA 19-9 and CEA in diagnosing cholangiocarcinoma-the influence of sampling time and hepatolithiasis. Hepatogastroenterology 2002; 49: 616-620.
37. Lamerz R. Role of tumour markers, cytogenetics. Ann Oncol 1999; 10(suppl 4): 145-149.
38. Maestranzi S, Przemioslo R, Mitchell H, et al. The effect of benign and malignant liver disease on the tumour markers CA19-9 and CEA. Ann Clin Biochem 1998; 35(part 1): 99-103. (Pubitemid 28043632)
39. Chalasani N, Baluyut A, Ismail A, et al. Cholangiocarcinoma in patients with primary sclerosing cholangitis: a multicenter case-control study. Hepatology 2000; 31: 7-11. (Pubitemid 30033681)
40. Nichols JC, Gores GJ, LaRusso NF, et al. Diagnostic role of serum CA 19-9 for cholangiocarcinoma in patients with primary sclerosing cholangitis. Mayo Clin Proc 1993; 68 874-879. (Pubitemid 23266123)
41. Siqueira E, Schoen RE, Silverman W, et al. Detecting cholangiocarcinoma in patients with primary sclerosing cholangitis. Gastrointest Endosc 2002; 56: 40-47. (Pubitemid 41115047)
42. Bamrungphon W, Prempracha N, Bunchu N, et al. A new mucin antibody/enzyme-linked lectin-sandwich assay of serum MUC5AC mucin for the diagnosis of cholangiocarcinoma. Cancer Lett 2007; 247: 301-308. (Pubitemid 46240619)
43. Sharma MP, Ahuja V. Aetiological spectrum of obstructive jaundice and diagnostic ability of ultrasonography: a clinician's perspective. Trop Gastroenterol 1999; 20: 167-169.
44. Bloom CM, Langer B, Wilson SR. Role of US in the detection, characterization, and staging of cholangiocarcinoma. Radiographics 1999; 19: 1199-1218.
45. Slattery JM, Sahani DV. What is the current state-of- the-art imaging for detection and staging of cholangiocarcinoma? Oncologist 2006; 11: 913-922. (Pubitemid 44373764)
46. Brugge WR. Advances in the endoscopic management of patients with pancreatic and biliary malignancies. South Med J 2006; 99: 1358-1366.
47. Valls C, Gumà A, Puig I, et al. Intrahepatic peripheral cholangiocarcinoma: CT evaluation. Abdom Imaging 2000; 25: 490-496.
48. Zhang Y, Uchida M, Abe T, et al. Intrahepatic peripheral cholangiocarcinoma: comparison of dynamic CT and dynamic MRI. J Comput Assist Tomogr 1999; 23: 670-677. (Pubitemid 29463798)
49. Tillich M, Mischinger HJ, Preisegger KH, et al. Multiphasic helical CT in diagnosis and staging of hilar cholangiocarcinoma. AJR Am J Roentgenol 1998; 171: 651-658. (Pubitemid 28406125)
50. Bach AM, Hann LE, Brown KT, et al. Portal vein evaluation with US: comparison to angiography combined with CT arterial portography. Radiology 1996; 201: 149-154. (Pubitemid 26314380)
51. Kim TK, Choi BI, Han JK, et al. Peripheral cholangiocarcinoma of the liver: two-phase spiral CT findings. Radiology 1997; 204: 539-543. (Pubitemid 27337509)
52. Han JK, Choi BI, Kim AY, et al. Cholangiocarcinoma: pictorial essay of CT and cholangiographic findings. Radiographics 2002; 22: 173-187.
53. Watadani T, Akahane M, Yoshikawa T, et al. Preoperative assessment of hilar cholangiocarcinoma using multidetector-row CT: correlation with histopathological findings. Radiat Med 2008; 26: 402-407.
54. Seo H, Lee JM, Kim IH, et al. Evaluation of the gross type and longitudinal extent of extrahepatic cholangiocarcinomas on contrast-enhanced multidetector row computed tomography. J Comput Assist Tomogr 2009; 33: 376-382.
55. Okumoto T, Sato A, Yamada T, et al. Correct diagnosis of vascular encasement and longitudinal extension of hilar cholangiocarcinoma by four-channel multidetector-row computed tomography. Tohoku J Exp Med 2009; 217: 1-8.
56. Feydy A, Vilgrain V, Denys A, et al. Helical CT assessment in hilar cholangiocarcinoma: correlation with surgical and pathologic findings. AJR Am J Roentgenol 1999; 172: 73-77. (Pubitemid 29028434)
57. Lee HY, Kim SH, Lee JM, et al. Preoperative assessment of resectability of hepatic hilar cholangiocarcinoma: combined CT and cholangiography with revised criteria. Radiology 2006; 239: 113-121.
58. Aloia TA, Charnsangavej C, Faria S, et al. High-resolution computed tomography accurately predicts resectability in hilar cholangiocarcinoma. Am J Surg 2007; 193: 702-706. (Pubitemid 46733908)
59. Xu AM, Cheng HY, Jiang WB, et al. Multi-slice three-dimensional spiral CT cholangiography: a new technique for diagnosis of biliary diseases. Hepatobiliary Pancreat Dis Int 2002; 1: 595-603.
60. Di Cesare E, Puglielli E, Michelini O, et al. Malignant obstructive jaundice: comparison of MRCP and ERCP in the evaluation of distal lesions [article in Italian]. Radiol Med (Torino) 2003; 105: 445-453. (Pubitemid 36958589)
61. Manfredi R, Brizi MG, Masselli G, et al. Malignant biliary hilar stenosis: MR cholangiography compared with direct cholangiography. Radiol Med 2001; 102: 48-54. (Pubitemid 33613800)
62. Rösch T, Meining A, Fröhmorgen S, et al. A prospective comparison of the diagnostic accuracy of ERCP, MRCP, CT, and EUS in biliary strictures. Gastrointest Endosc 2002; 55: 870-876. (Pubitemid 41127905)
63. Park MS, Kim TK, Kim KW, et al. Differentiation of extrahepatic bile duct cholangiocarcinoma from benign stricture: findings at MRCP versus ERCP. Radiology 2004; 233: 234-240. (Pubitemid 39280979)
64. Varghese JC, Farrell MA, Courtney G, et al. A prospective comparison of magnetic resonance cholangiopancreatography with endoscopic retrograde cholangiopancreatography in the evaluation of patients with suspected biliary tract disease. Clin Radiol 1999; 54: 513-520. (Pubitemid 29417687)
65. Loperfido S, Angelini G, Benedetti G, et al. Major early complications from diagnostic and therapeutic ERCP: a prospective multicenter study. Gastrointest Endosc 1998; 48: 1-10. (Pubitemid 28337421)
66. Lopera JE, Soto JA, Múnera F. Malignant hilar and perihilar biliary obstruction: use of MR cholangiography to define the extent of biliary ductal involvement and plan percutaneous interventions. Radiology 2001; 220: 90-96. (Pubitemid 32577965)
67. Manfredi R, Barbaro B, Masselli G, et al. Magnetic resonance imaging of cholangiocarcinoma. Semin Liver Dis 2004; 24: 155-164. (Pubitemid 38738344)
68. Fulcher AS, Turner MA. HASTE MR cholangiography in the evaluation of hilar cholangiocarcinoma. AJR Am J Roentgenol 1997; 169: 1501-1505. (Pubitemid 127469768)
69. Choi BI, Lee JM, Han JK. Imaging of intrahepatic and hilar cholangiocarcinoma. Abdom Imaging 2004; 29: 548-557. (Pubitemid 39095753)
70. Lee JW, Han JK, Kim TK, et al. CT features of intraductal intrahepatic cholangiocarcinoma. AJR Am J Roentgenol 2000; 175: 721-725.
71. Lee SS, Kim MH, Lee SK, et al. MR cholangiography versus cholangioscopy for evaluation of longitudinal extension of hilar cholangiocarcinoma. Gastrointest Endosc 2002; 56: 25-32. (Pubitemid 41115045)
72. Harewood GC, Baron TH, Stadheim LM, et al. Prospective, blinded assessment of factors influencing the accuracy of biliary cytology interpretation. Am J Gastroenterol 2004; 99: 1464-1469. (Pubitemid 39180092)
73. Domagk D, Poremba C, Dietl KH, et al. Endoscopic transpapillary biopsies and intraductal ultrasonography in the diagnostics of bile duct strictures: a prospective study. Gut 2002; 51: 240-244. (Pubitemid 34791454)
74. Baskin-Bey ES, Moreno Luna LE, Gores GJ. Diagnosis of cholangiocarcinoma in patients with PSC: a sight on cytology. J Hepatol 2006; 45: 476-479. (Pubitemid 44307388)
75. Kipp BR, Stadheim LM, Halling SA, et al. A comparison of routine cytology and fluorescence in situ hybridization for the detection of malignant bile duct strictures. Am J Gastroenterol 2004; 99: 1675-1681. (Pubitemid 39237490)
76. Fukuda Y, Tsuyuguchi T, Sakai Y, et al. Diagnostic utility of peroral cholangioscopy for various bile-duct lesions. Gastrointest Endosc 2005; 62: 374-382. (Pubitemid 41187939)
77. Meining A, Frimberger E, Becker V, et al. Detection of cholangiocarcinoma in vivo using miniprobebased confocal fluorescence microscopy. Clin Gastroenterol Hepatol 2008; 6: 1057-1060.
78. Lee JH, Salem R, Aslanian H, et al. Endoscopic ultrasound and fine needLe aspiration of unexplained bile duct strictures. Am J Gastroenterol 2004; 99: 1069-1073. (Pubitemid 38917810)
79. Fritscher-Ravens A, Broering DC, Sriram PV, et al. EUS-guided fine needLe aspiration cytodiagnosis of hilar cholangiocarcinoma: a case series. Gastrointest Endosc 2000; 52: 534-540.
80. Dumonceau JM, Polkowski M, Larghi A, et al. Indications, results, and clinical impact of endoscopicultrasound (EUS)-guided sampling in gastroenterology: European Society of Gastrointestinal Endoscopy (ESGE) Clinical Guideline. Endoscopy 2011; 43: 897-912.
81. Eloubeidi MA, Chen VK, Jhala NC, et al. Endoscopic ultrasound guided fine needLe aspiration biopsy of suspected cholangiocarcinoma. Clin Gastroenterol Hepatol 2004; 2: 209-213. (Pubitemid 38293307)
82. Brugge WR. Endoscopic techniques to diagnose and manage biliary tumors. J Clin Oncol 2005; 23: 4561-4565. (Pubitemid 46196587)
83. Vazquez-Sequeiros E, Baron TH, Clain JE, et al. Evaluation of indeterminate bile duct strictures by intraductal US. Gastrointest Endosc 2002; 56: 372-379.
84. Farrell RJ, Agarwal B, Brandwein SL, et al. Intraductal US is a useful adjunct to ERCP for distinguishing malignant from benign biliary strictures. Gastrointest Endosc 2002; 56: 681-687. (Pubitemid 36531703)
85. Poneros JM, Tearney GJ, Shiskov M, et al. Optical coherence tomography of the biliary tree during ERCP. Gastrointest Endosc 2002; 55: 84-88. (Pubitemid 41122934)
86. Singh P, Chak A, Willis JE, et al. In vivo optical coherence tomography imaging of the pancreatic and biliary ductal system. Gastrointest Endosc 2005; 62: 970-974. (Pubitemid 41654439)
87. Arvanitakis M, Hookey L, Tessier G, et al. Intraductal optical coherence tomography during endoscopic retrograde cholangiopancreatography for investigation of biliary strictures. Endoscopy 2009; 41: 696-701.
88. Wakabayashi H, Akamoto S, Yachida C, et al. Significance of fluorodeoxyglucose PET imaging in the diagnosis of malignancies in patients with biliary stricture. Eur J Surg Oncol 2005; 31: 1175-1179. (Pubitemid 41819204)
89. Petrowsky H, Wildbrett P, Husarik DB, et al. Impact of integrated positron emission tomography and computed tomography on staging and management of gallbladder cancer and cholangiocarcinoma. J Hepatol 2006; 45: 43-50. (Pubitemid 43850623)
90. Sakamoto E, Nimura Y, Hayakawa N, et al. The pattern of infiltration at the proximal border of hilar bile duct carcinoma: a histologic analysis of 62 resected cases. Ann Surg 1998; 227: 405-411. (Pubitemid 28131022)
91. Ebata T, Watanabe H, Ajioka Y, et al. Pathological appraisal of lines of resection for bile duct carcinoma. Br J Surg 2002; 89: 1260-1267. (Pubitemid 36002543)
92. He P, Shi JS, Chen WK, et al. Multivariate statistical analysis of clinicopathologic factors influencing survival of patients with bile duct carcinoma. World J Gastroenterol 2002; 8: 943-946.
93. Jarnagin WR, Fong Y, DeMatteo RP, et al. Staging, resectability, and outcome in 225 patients with hilar cholangiocarcinoma. Ann Surg 2001; 234: 507-519. (Pubitemid 32946713)
94. Nagorney DM, Kendrick ML. Hepatic resection in the treatment of hilar cholangiocarcinoma. Adv Surg 2006; 40: 159-171. (Pubitemid 44648288)
95. Seyama Y, Makuuchi M. Current surgical treatment for bile duct cancer. World J Gastroenterol 2007; 13: 1505-1515. (Pubitemid 46672657)
96. Kitagawa Y, Nagino M, Kamiya J, et al. Lymph node metastasis from hilar cholangiocarcinoma: audit of 110 patients who underwent regional and paraaortic node dissection. Ann Surg 2001; 233: 385-392. (Pubitemid 32187818)
97. Greene FL, American Joint Committee on Cancer, American Cancer Society. AJCC Cancer Staging Manual. 6th ed. New York, NY: Springer-Verlag; 2002.
98. Farges O, Fuks D, Le Treut YP, et al. AJCC 7th edition of TNM staging accurately discriminates outcomes of patients with resectable intrahepatic cholangiocarcinoma: by the AFC-IHCC-2009 study group. Cancer 2011; 117: 2170-2177.
99. Nathan H, Aloia TA, Vauthey JN, et al. A proposed staging system for intrahepatic cholangiocarcinoma. Ann Surg Oncol 2009; 16: 14-22.
100. Taylor-Robinson SD, Foster GR, Arora S, et al. Increase in primary liver cancer in the UK, 1979-94. Lancet 1997; 350: 1142-1143. (Pubitemid 27454010)
101. Patel T. Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States. Hepatology 2001; 33: 1353-1357. (Pubitemid 32496970)
102. Jarnagin WR, Shoup M. Surgical management of cholangiocarcinoma. Semin Liver Dis 2004; 24: 189-199. (Pubitemid 38738347)
103. Shimoda M, Kubota K. Multi-disciplinary treatment for cholangiocellular carcinoma. World J Gastroenterol 2007; 13: 1500-1504. (Pubitemid 46672656)
104. Su CH, Tsay SH, Wu CC, et al. Factors influencing postoperative morbidity, mortality, and survival after resection for hilar cholangiocarcinoma. Ann Surg 1996; 223: 384-394. (Pubitemid 26115275)
105. Sewnath ME, Karsten TM, Prins MH, et al. A meta-analysis on the efficacy of preoperative biliary drainage for tumors causing obstructive jaundice. Ann Surg 2002; 236: 17-27. (Pubitemid 34686446)
106. Aly EA, Johnson CD. Preoperative biliary drainage before resection in obstructive jaundice. Dig Surg 2001; 18: 84-89. (Pubitemid 32437049)
107. Nakeeb A, Pitt HA. The role of preoperative biliary decompression in obstructive jaundice. Hepatogastroenterology 1995; 42: 332-337.
108. Kawasaki S, Imamura H, Kobayashi A, et al. Results of surgical resection for patients with hilar bile duct cancer: application of extended hepatectomy after biliary drainage and hemihepatic portal vein embolization. Ann Surg 2003; 238: 84-92. (Pubitemid 38176411)
109. Nagino M, Kamiya J, Nishio H, et al. Two hundred forty consecutive portal vein embolizations before extended hepatectomy for biliary cancer: surgical outcome and long-term follow-up. Ann Surg 2006; 243: 364-372. (Pubitemid 43327769)
110. Abdalla EK, Barnett CC, Doherty D, et al. Extended hepatectomy in patients with hepatobiliary malignancies with and without preoperative portal vein embolization. Arch Surg 2002; 137: 675-681. (Pubitemid 34603012)
111. Abdalla EK, Hicks ME, Vauthey JN. Portal vein embolization: rationale, technique and future prospects. Br J Surg 2001; 88: 165-175. (Pubitemid 32142701)
112. Hemming AW, Reed AI, Howard RJ, et al. Preoperative portal vein embolization for extended hepatectomy. Ann Surg 2003; 237: 686-693. (Pubitemid 38174535)
113. Forsmo HM, Horn A, Viste A, et al. Survival and an overview of decision-making in patients with cholangiocarcinoma. Hepatobiliary Pancreat Dis Int 2008; 7: 412-417.
114. Anderson CD, Pinson CW, Berlin J, et al. Diagnosis and treatment of cholangiocarcinoma. Oncologist 2004; 9: 43-57. (Pubitemid 38134013)
115. Corvera CU, Weber SM, Jarnagin WR. Role of laparoscopy in the evaluation of biliary tract cancer. Surg Oncol Clin N Am 2002; 11: 877-891.
116. Goere D, Wagholikar GD, Pessaux P, et al. Utility of staging laparoscopy in subsets of biliary cancers: laparoscopy is a powerful diagnostic tool in patients with intrahepatic and gallbladder carcinoma. Surg Endosc 2006; 20: 721-725.
117. Weber SM, DeMatteo RP, Fong Y, et al. Staging laparoscopy in patients with extrahepatic biliary carcinoma: analysis of 100 patients. Ann Surg 2002; 235: 392-399. (Pubitemid 34183890)
118. Connor S, Barron E, Wigmore SJ, et al. The utility of laparoscopic assessment in the preoperative staging of suspected hilar cholangiocarcinoma. J Gastrointest Surg 2005; 9: 476-480. (Pubitemid 40431723)
119. Carriaga MT, Henson DE. Liver, gallbladder, extra-hepatic bile ducts, and pancreas. Cancer 1995; 75: 171-190.
120. Uenishi T, Kubo S, Yamazaki O, et al. Indications for surgical treatment of intrahepatic cholangiocarcinoma with lymph node metastases. J Hepatobiliary Pancreat Surg 2008; 15: 417-422.
121. Shimada M, Yamashita Y, Aishima S, et al. Value of lymph node dissection during resection of intrahepatic cholangiocarcinoma. Br J Surg 2001; 88: 1463-1466. (Pubitemid 32989464)
122. Shimada K, Sano T, Nara S, et al. Therapeutic value of lymph node dissection during hepatectomy in patients with intrahepatic cholangiocellular carcinoma with negative lymph node involvement. Surgery 2009; 145: 411-416.
123. Miwa S, Miyagawa S, Kobayashi A, et al. Predictive factors for intrahepatic cholangiocarcinoma recurrence in the liver following surgery. J Gastroenterol 2006; 41: 893-900. (Pubitemid 44594231)
124. Jan YY, Yeh CN, Yeh TS, et al. Clinicopathological factors predicting long-term overall survival after hepatectomy for peripheral cholangiocarcinoma. World J Surg 2005; 29: 894-898.
125. Ohtsuka M, Ito H, Kimura F, et al. Extended hepatic resection and outcomes in intrahepatic cholangiocarcinoma. J Hepatobiliary Pancreat Surg 2003; 10: 259-264. (Pubitemid 37407515)
126. Uenishi T, Hirohashi K, Kubo S, et al. Histologic factors affecting prognosis following hepatectomy for intrahepatic cholangiocarcinoma. World J Surg 2001; 25: 865-869. (Pubitemid 32666385)
127. Inoue K, Makuuchi M, Takayama T, et al. Longterm survival and prognostic factors in the surgical treatment of mass-forming type cholangiocarcinoma. Surgery 2000; 127: 498-505. (Pubitemid 30257507)
128. Yamamoto M, Takasaki K, Yoshikawa T. Extended resection for intrahepatic cholangiocarcinoma in Japan. J Hepatobiliary Pancreat Surg 1999; 6: 117-121.
129. Madariaga JR, Iwatsuki S, Todo S, et al. Liver resection for hilar and peripheral cholangiocarcinomas: a study of 62 cases. Ann Surg 1998; 227: 70-79. (Pubitemid 28071340)
130. Hanazaki K, Kajikawa S, Shimozawa N, et al. Prognostic factors of intrahepatic cholangiocarcinoma after hepatic resection: univariate and multivariate analysis. Hepatogastroenterology 2002; 49: 311-316. (Pubitemid 34606541)
131. Hirohashi K, Uenishi T, Kubo S, et al. Macroscopic types of intrahepatic cholangiocarcinoma: clinicopathologic features and surgical outcomes. Hepatogastroenterology 2002; 49: 326-329. (Pubitemid 34606544)
132. Todoroki T, Kawamoto T, Koike N, et al. Radical resection of hilar bile duct carcinoma and predictors of survival. Br J Surg 2000; 87: 306-313. (Pubitemid 30156356)
133. Hasegawa S, Ikai I, Fujii H, et al. Surgical resection of hilar cholangiocarcinoma: analysis of survival and postoperative complications. World J Surg 2007; 31: 1256-1263. (Pubitemid 47029903)
134. Dinant S, Gerhards MF, Rauws EA, et al. Improved outcome of resection of hilar cholangiocarcinoma (Klatskin tumor). Ann Surg Oncol 2006; 13: 872-880. (Pubitemid 43727373)
135. Kawarada Y, Das BC, Naganuma T, et al. Surgical treatment of hilar bile duct carcinoma: experience with 25 consecutive hepatectomies. J Gastrointest Surg 2002; 6: 617-624. (Pubitemid 40433517)
136. Tabata M, Kawarada Y, Yokoi H, et al. Surgical treatment for hilar cholangiocarcinoma. J Hepatobiliary Pancreat Surg 2000; 7: 148-154.
137. Kosuge T, Yamamoto J, Shimada K, et al. Improved surgical results for hilar cholangiocarcinoma with procedures including major hepatic resection. Ann Surg 1999; 230: 663-671. (Pubitemid 30191828)
138. Miyazaki M, Ito H, Nakagawa K, et al. Aggressive surgical approaches to hilar cholangiocarcinoma: hepatic or local resection? Surgery 1998; 123: 131-136. (Pubitemid 28110073)
139. Shimada H, Endo I, Sugita M, et al. Hepatic resection combined with portal vein or hepatic artery reconstruction for advanced carcinoma of the hilar bile duct and gallbladder. World J Surg 2003; 27: 1137-1142. (Pubitemid 37259994)
140. Cheng Q, Luo X, Zhang B, et al. Distal bile duct carcinoma: prognostic factors after curative surgery: a series of 112 cases. Ann Surg Oncol 2007; 14: 1212-1219.
141. Seiler CA, Wagner M, Sadowski C, et al. Randomized prospective trial of pylorus-preserving vs classic duodenopancreatectomy (Whipple procedure): initial clinical results. J Gastrointest Surg 2000; 4: 443-452.
142. Riall TS, Cameron JL, Lillemoe KD, et al. Pancreaticoduodenectomy with or without distal gastrectomy and extended retroperitoneal lymphadenectomy for periampullary adenocarcinoma-part 3: update on 5-year survival. J Gastrointest Surg 2005; 9: 1191-1206. (Pubitemid 41751111)
143. Wade TP, Prasad CN, Virgo KS, et al. Experience with distal bile duct cancers in US Veterans Affairs hospitals: 1987-1991. J Surg Oncol 1997; 64: 242-245. (Pubitemid 27157415)
144. Murakami Y, Uemura K, Hayashidani Y, et al. Pancreatoduodenectomy for distal cholangiocarcinoma: prognostic impact of lymph node metastasis. World J Surg 2007; 31: 337-344.
145. Yoshida T, Matsumoto T, Sasaki A, et al. Prognostic factors after pancreatoduodenectomy with extended lymphadenectomy for distal bile duct cancer. Arch Surg 2002; 137: 69-73. (Pubitemid 34041823)
146. Endo I, Gonen M, Yopp AC, et al. Intrahepatic cholangiocarcinoma: rising frequency, improved survival, and determinants of outcome after resection. Ann Surg 2008; 248: 84-96.
147. Jonas S, Thelen A, Benckert C, et al. Extended liver resection for intrahepatic cholangiocarcinoma: a comparison of the prognostic accuracy of the fifth and sixth editions of the TNM classification. Ann Surg 2009; 249: 303-309.
148. Lang H, Sotiropoulos GC, Sgourakis G, et al. Operations for intrahepatic cholangiocarcinoma: single-institution experience of 158 patients. J Am Coll Surg 2009; 208: 218-228.
149. Chen XP, Lau WY, Huang ZY, et al. Extent of liver resection for hilar cholangiocarcinoma. Br J Surg 2009; 96: 1167-1175.
150. Heimbach JK, Gores GJ, Haddock MG, et al. Predictors of disease recurrence following neoadjuvant chemotherapy and liver transplantation for unresectable perihilar cholangiocarcinoma. Transplantation 2006; 82: 1703-1707. (Pubitemid 46035655)
151. Sudan D, DeRoover A, Chinnakotla S, et al. Radio-chemotherapy and transplantation allow long-term survival for nonresectable hilar cholangiocarcinoma. Am J Transplant 2002; 2: 774-779. (Pubitemid 36342621)
152. Hong JC, Jones CM, Duffy JP, et al. Comparative analysis of resection and liver transplantation for intrahepatic and hilar cholangiocarcinoma: a 24-year experience in a single center. Arch Surg 2011; 146: 683-689.
153. Rea DJ, Heimbach JK, Rosen CB, et al. Liver transplantation with neoadjuvant chemoradiation is more effective than resection for hilar cholangiocarcinoma. Ann Surg 2005; 242: 451-461. (Pubitemid 41306608)
154. Becker NS, Rodriguez JA, Barshes NR, et al. Outcomes analyses for 280 patients with cholangiocarcinoma treated with liver transplantation over an 18-year period. J Gastrointest Surg 2008; 12: 117-122.
155. Sotiropoulos GC, Kaiser GM, Lang H, et al. Liver transplantation as a primary indication for intrahepatic cholangiocarcinoma: a single center experience. Transplant Proc 2008; 40: 3194-3195.
156. Hu XX, Yan LN. Retrospective analysis of prognostic factors after liver transplantation for intrahepatic cholangiocarcinoma in China: a single-center experience. Hepatogastroenterology 2011; 58: 1255-1259.
157. Friman S, Foss A, Isoniemi H, et al. Liver transplantation for cholangiocarcinoma: selection is essential for acceptable results. Scand J Gastroenterol 2011; 46: 370-375.
158. Murakami Y, Uemura K, Sudo T, et al. Gemcitabine-based adjuvant chemotherapy improves survival after aggressive surgery for hilar cholangiocarcinoma. J Gastrointest Surg 2009; 13: 1470-1479.
159. Murakami Y, Uemura K, Sudo T, et al. Prognostic factors after surgical resection for intrahepatic, hilar and distal cholangiocarcinoma. Ann Surg Oncol 2011; 18: 651-658.
160. Todoroki T, Ohara K, Kawamoto T, et al. Benefits of adjuvant radiotherapy after radical resection of locally advanced main hepatic duct carcinoma. Int J Radiat Oncol Biol Phys 2000; 46: 581-587. (Pubitemid 30100635)
161. Hughes MA, Frassica DA, Yeo CJ, et al. Adjuvant concurrent chemoradiation for adenocarcinoma of the distal common bile duct. Int J Radiat Oncol Biol Phys 2007; 68: 178-182. (Pubitemid 46589827)
162. Gerhards MF, van Gulik TM, Gonzalez GD, et al. Results of postoperative radiotherapy for resectable hilar cholangiocarcinoma. World J Surg 2003; 27: 173-179. (Pubitemid 36920167)
163. Sagawa N, Kondo S, Morikawa T, et al. Effectiveness of radiation therapy after surgery for hilar cholangiocarcinoma. Surg Today 2005; 35: 548-552. (Pubitemid 40854019)
164. Heimbach JK, Gores GJ, Haddock MG, et al. Liver transplantation for unresectable perihilar cholangiocarcinoma. Semin Liver Dis 2004; 24: 201-207. (Pubitemid 38738348)
165. Abu-Hamda EM, Baron TH. Endoscopic management of cholangiocarcinoma. Semin Liver Dis 2004; 24: 165-175. (Pubitemid 38738345)
166. Davids PH, Groen AK, Rauws EA, et al. Randomised trial of self-expanding metal stents versus polyethylene stents for distal malignant biliary obstruction. Lancet 1992; 340: 1488-1492.
167. Paik WH, Park YS, Hwang JH, et al. Palliative treatment with self-expandable metallic stents in patients with advanced type III or IV hilar cholangiocarcinoma: a percutaneous versus endoscopic approach. Gastrointest Endosc 2009; 69: 55-62.
168. De Palma GD, Galloro G, Siciliano S, et al. Unilateral versus bilateral endoscopic hepatic duct drainage in patients with malignant hilar biliary obstruction: results of a prospective, randomized, and controlled study. Gastrointest Endosc 2001; 53: 547-553. (Pubitemid 33587025)
169. Smith AC, Dowsett JF, Russell RC, et al. Randomised trial of endoscopic stenting versus surgical bypass in malignant low bile duct obstruction. Lancet 1994; 344: 1655-1660. (Pubitemid 24371094)
170. Shepherd HA, Royle G, Ross AP, et al. Endoscopic biliary endoprosthesis in the palliation of malignant obstruction of the distal common bile duct: a randomized trial. Br J Surg 1988; 75: 1166-1168. (Pubitemid 19002642)
171. Ohnishi H, Asada M, Shichijo Y, et al. External radiotherapy for biliary decompression of hilar cholangiocarcinoma. Hepatogastroenterology 1995; 42: 265-268.
172. Cameron JL, Pitt HA, Zinner MJ, et al. Management of proximal cholangiocarcinomas by surgical resection and radiotherapy. Am J Surg 1990; 159: 91-98. (Pubitemid 20045317)
173. Bruha R, Petrtyl J, Kubecova M, et al. Intraluminal brachytherapy and self-expandable stents in nonresectable biliary malignancies-the question of long-term palliation. Hepatogastroenterology 2001; 48: 631-637. (Pubitemid 32619648)
174. Choi CW, Choi IK, Seo JH, et al. Effects of 5- fluorouracil and leucovorin in the treatment of pancreatic-biliary tract adenocarcinomas. Am J Clin Oncol 2000; 23: 425-428. (Pubitemid 32429160)
175. Patt YZ, Jones DV Jr, Hoque A, et al. Phase II trial of intravenous flourouracil and subcutaneous interferon alfa-2b for biliary tract. Cancer J Clin Oncol 1996; 14: 2311-2315. (Pubitemid 26264882)
176. Ducreux M, Rougier P, Fandi A, et al. Effective treatment of advanced biliary tract carcinoma using 5-fluorouracil continuous infusion with cisplatin. Ann Oncol 1998; 9: 653-656. (Pubitemid 28318199)
177. Nehls O, Klump B, Arkenau HT, et al. Oxaliplatin, fluorouracil and leucovorin for advanced biliary system adenocarcinomas: a prospective phase II trial. Br J Cancer 2002; 87: 702-704. (Pubitemid 35178744)
178. Kubicka S, Rudolph KL, Tietze MK, et al. Phase II study of systemic gemcitabine chemotherapy for advanced unresectable hepatobiliary carcinomas. Hepatogastroenterology 2001; 48: 783-789. (Pubitemid 32619681)
179. Lee GW, Kang JH, Kim HG, et al. Combination chemotherapy with gemcitabine and cisplatin as first-line treatment for immunohistochemically proven cholangiocarcinoma. Am J Clin Oncol 2006; 29: 127-131. (Pubitemid 44270949)
180. Knox JJ, HedLey D, Oza A, et al. Combining gemcitabine and capecitabine in patients with advanced biliary cancer: a phase II trial. J Clin Oncol 2005; 23: 2332-2338.
181. André; T, Tournigand C, Rosmorduc O, et al. Gemcitabine combined with oxaliplatin (GEMOX) in advanced biliary tract adenocarcinoma: a GERCOR study. Ann Oncol 2004; 15: 1339-1343.
182. Valle J, Wasan H, Palmer DH, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 2010; 362: 1273-1281.
183. Lubner SJ, Mahoney MR, Kolesar JL, et al. Report of a multicenter phase II trial testing a combination of biweekly bevacizumab and daily erlotinib in patients with unresectable biliary cancer: a phase II consortium study. J Clin Oncol 2010; 28: 3491-3497.
184. Berr F, Wiedmann M, Tannapfel A, et al. Photodynamic therapy for advanced bile duct cancer: evidence for improved palliation and extended survival. Hepatology 2000; 31: 291-298. (Pubitemid 30078590)
185. Ortner ME, Caca K, Berr F, et al. Successful photodynamic therapy for nonresectable cholangiocarcinoma: a randomized prospective study. Gastroenterology 2003; 125: 1355-1363. (Pubitemid 37409755)